Strong Earnings Beat#
CVS Health's stock surged by 7.23% in morning trading after the company reported impressive first-quarter earnings for 2026. The adjusted earnings per share (EPS) came in at $2.57, significantly higher than analysts' expectations of around $2.21, marking a surprise of about 16%. Additionally, CVS reported revenues of $100.4 billion, surpassing the anticipated $95 billion.
Improved Business Segments#
The company's performance was bolstered by improvements across all its business segments, including its insurance division, Aetna, retail pharmacy, and health services. The increase in adjusted EPS was mainly due to better operating income in the Health Care Benefits segment, which is part of CVS's strategy to recover its profit margins.
Updated Guidance#
CVS has raised its full-year 2026 adjusted EPS guidance from a range of $7.00–$7.20 to $7.30–$7.50. The company also increased its cash flow from operations guidance to at least $9.5 billion, up from $9.0 billion. CFO Brian Newman highlighted that much of the revenue increase is attributed to positive trends in Aetna's performance.
Market Context#
The broader market also contributed to CVS's stock rise, with major indices like the S&P 500, Dow Jones, and NASDAQ all posting gains. CVS's strong quarterly results align with a generally positive performance in the health insurance sector, although the upcoming second quarter will be critical for assessing medical costs. Notably, the Health Care Benefits segment's adjusted operating income rose by 52.6% year-over-year, reflecting improved performance and the absence of a significant reserve recorded last year.
Overall, CVS's strong earnings, updated guidance, and ongoing turnaround efforts have renewed investor confidence, leading to a new 52-week high for the stock. The company has maintained its dividend payments for 56 consecutive years, rewarding long-term shareholders.